Copaxone starts late-stage glaucoma trial; Intercell launches Phase I study;

Vaccine Research

Researchers have begun a late-stage trial of Copaxone--currently used for MS patients--to test its ability to guard against the nerve damage caused by glaucoma. Report

Intercell says it has launched a Phase I clinical trial of its IC47 vaccine candidate to prevent disease caused by the bacterium Streptococcus pneumoniae. Release

Researchers in Taiwan say they will be ready to begin clinical trials of an emergency bird flu vaccine in the second half of this year. The vaccine was developed at the National Health Research Institute. Report

The FDA has provided orphan drug status to two experimental cancer vaccines developed at the University of Maryland, Baltimore and licensed to Gliknik. Report

Vaccine market

The CDC says that the flu season has begun to wind down, noting that this has been one of the mildest in years. One big reason why the flu has not hit hard, adds the CDC, is that this year's seasonal vaccine was more closely targeted at the viruses in circulation. Report

The FDA has approved a rapid test to detect bird flu in humans. Report

Officials at the UK's Medicines and Healthcare products Regulatory Agency say that patients who received the Engerix B hepatitis vaccine between March 9 and April 6 need to be re-vaccinated. One batch of the vax was evidently made ineffective after it was accidentally frozen. Story

A low-risk strain of bird flu has been found at a poultry farm in Kentucky. Report

Suggested Articles

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.

Takeda has spent considerable resources on its phase 3 dengue vaccine, and now data show the shot was 80% effective in preventing dengue.